An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors

NCT07359066 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

210

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
PARP Inhibitor

Interventions

DRUG: SRP1020

Sponsor

Shanghai SciBrunch Therapeutics Co., Ltd.